Compare Abeona Therapeutics Inc (ABEO) vs Expedia Group Inc (EXPE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Expedia Group Inc — how do they compare? Abeona Therapeutics Inc trades at $6.72 (market cap $373.32M), while Expedia Group Inc trades at $257.79 (market cap $32.39B). The key difference: Expedia Group Inc is far larger — about 86.8× Abeona Therapeutics Inc's market cap, and Expedia Group Inc pays a 0.65% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | EXPE | |
|---|---|---|
Market Cap | $373.32M | $32.39B |
Sector | Health | Consumer Cyclical |
52-Week High | $7.23 | $301.31 |
52-Week Low | $4.17 | $176.09 |
Enterprise Value | $228.22M | $31.30B |
Dividend Yield | — | 0.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Expedia Group (EXPE) trades at $269.87, up 0.44% with a bullish technical outlook supported by moving averages and strong fundamental performance. The company reported consistent earnings beats in recent quarters with Q1 2026 EPS of $1.96 exceeding expectations of $1.41. Revenue growth has been steady, climbing from $11.7B in 2022 to $14.7B in 2025, while maintaining robust profitability with a 90.27% gross margin. Recent developments include the CarTrawler acquisition and positive travel industry research positioning the company for continued growth.
EXPE presents a compelling investment case with analyst consensus price target of $281.75 representing 4.4% upside potential. The stock offers exposure to the resilient travel sector with improving operational efficiency and strong cash flow generation. Key risks include travel sector volatility and competitive pressures, but the company's technological innovation and market position provide defensive characteristics in the evolving travel landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Expedia Group Inc
Expedia is the world's largest online travel agency by bookings, offering services for lodging (75% of total 2021 sales), air tickets (3%), rental cars, cruises, in-destination, and other (15%), and advertising revenue (7%). Expedia operates a number of branded travel booking sites, including Expedia.com, Hotels.com, Travelocity, Orbitz, Wotif, AirAsia, and Vrbo. It has also expanded into travel media with the acquisition of Trivago. Transaction fees for online bookings account for the bulk of sales and profits.
Read more on EXPE →
